Implantation and Injectable Dosage Form New Animal Drugs; Oxytetracycline Injection

Riepilogo

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer Animal Health. The supplemental NADA provides for subcutaneous use of oxytetracycline injection in addition to intramuscular and intravenous use in beef cattle and nonlactating dairy cattle, and calves including preruminating (veal) calves.